NASDAQ:CARA - Cara Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$18.92 -0.02 (-0.11 %)
(As of 08/20/2018 04:00 PM ET)
Previous Close$18.94
Today's Range$18.65 - $19.05
52-Week Range$11.11 - $22.29
Volume447,700 shs
Average Volume1.08 million shs
Market Capitalization$768.13 million
P/E Ratio-10.13
Dividend YieldN/A
Beta2.89
Cara Therapeutics logoCara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Receive CARA News and Ratings via Email

Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CARA
CUSIPN/A
Phone203-406-3700

Debt

Debt-to-Equity RatioN/A
Current Ratio3.98
Quick Ratio3.98

Price-To-Earnings

Trailing P/E Ratio-10.13
Forward P/E Ratio-9.32
P/E GrowthN/A

Sales & Book Value

Annual Sales$910,000.00
Price / Sales816.89
Cash FlowN/A
Price / CashN/A
Book Value$2.66 per share
Price / Book7.11

Profitability

EPS (Most Recent Fiscal Year)($1.86)
Net Income$-58,120,000.00
Net MarginsN/A
Return on Equity-73.21%
Return on Assets-56.94%

Miscellaneous

Employees37
Outstanding Shares39,290,000
Market Cap$768.13 million

Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics Inc (NASDAQ:CARA) posted its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.02. The biopharmaceutical company had revenue of $2.87 million for the quarter, compared to analysts' expectations of $0.63 million. View Cara Therapeutics' Earnings History.

When is Cara Therapeutics' next earnings date?

Cara Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, November, 1st 2018. View Earnings Estimates for Cara Therapeutics.

What price target have analysts set for CARA?

10 Wall Street analysts have issued 1 year price targets for Cara Therapeutics' stock. Their forecasts range from $21.00 to $31.50. On average, they expect Cara Therapeutics' stock price to reach $25.8636 in the next year. This suggests a possible upside of 36.7% from the stock's current price. View Analyst Price Targets for Cara Therapeutics.

What is the consensus analysts' recommendation for Cara Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cara Therapeutics.

What are Wall Street analysts saying about Cara Therapeutics stock?

Here are some recent quotes from research analysts about Cara Therapeutics stock:
  • 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (7/30/2018)
  • 2. HC Wainwright analysts commented, "We view this as a clear positive for the company, as it brings in minimally- dilutive financing ($50M cash plus $20M equity investment at $17/ share), validates our view on Korsuva, and de-risks the U.S. commercial launch. Despite the headline ex-US deal, we’re more focused on the new U.S. arrangement here because we don’t yet include ex-US in our model until we get more clarity on the regulatory and reimbursement landscape (our valuation is all-U.S.), and we assume the U.S. was also the primary value driver here for Vifor Fresenius as well. Vifor Fresenius is a JV of Vifor (VIFN:SW) and Fresenius Medical Care AG (FMS; not covered). We believe Vifor Fresenius is the best possible commercial partner for Cara, with Fresenius itself owning nearly 40% of U.S. dialysis centers." (5/23/2018)

Who are some of Cara Therapeutics' key competitors?

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the folowing people:
  • Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 54)
  • Dr. Mani Mohindru, CFO & Chief Strategy Officer (Age 46)
  • Dr. Joseph Stauffer, Chief Medical Officer (Age 52)
  • Dr. Michael E. Lewis Ph.D., Co-Founder and Chief Scientific Advisor (Age 66)
  • Mr. Scott M. Terrillion, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 55)

Has Cara Therapeutics been receiving favorable news coverage?

Press coverage about CARA stock has trended somewhat negative recently, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cara Therapeutics earned a media and rumor sentiment score of -0.11 on Accern's scale. They also gave media stories about the biopharmaceutical company an impact score of 47.02 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future. View Recent Headlines for Cara Therapeutics.

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.92%), Chescapmanager LLC (2.96%), First Manhattan Co. (1.47%), Nexthera Capital LP (1.11%), Marshall Wace LLP (0.89%) and C WorldWide Group Holding A S (0.77%). Company insiders that own Cara Therapeutics stock include Dean Slagel, Derek T Chalmers, Frederique PhD Menzaghi and Ventures Vi Lp Rho. View Institutional Ownership Trends for Cara Therapeutics.

Which institutional investors are selling Cara Therapeutics stock?

CARA stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, DAFNA Capital Management LLC, Janney Montgomery Scott LLC and Mesirow Financial Investment Management Inc.. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers and Frederique PhD Menzaghi. View Insider Buying and Selling for Cara Therapeutics.

Which institutional investors are buying Cara Therapeutics stock?

CARA stock was purchased by a variety of institutional investors in the last quarter, including First Manhattan Co., Marshall Wace LLP, Chescapmanager LLC, Nexthera Capital LP, BlackRock Inc., Cypress Capital Management LLC WY, C WorldWide Group Holding A S and Bank of America Corp DE. View Insider Buying and Selling for Cara Therapeutics.

How do I buy shares of Cara Therapeutics?

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $18.92.

How big of a company is Cara Therapeutics?

Cara Therapeutics has a market capitalization of $768.13 million and generates $910,000.00 in revenue each year. The biopharmaceutical company earns $-58,120,000.00 in net income (profit) each year or ($1.86) on an earnings per share basis. Cara Therapeutics employs 37 workers across the globe.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700.


MarketBeat Community Rating for Cara Therapeutics (NASDAQ CARA)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  480 (Vote Outperform)
Underperform Votes:  236 (Vote Underperform)
Total Votes:  716
MarketBeat's community ratings are surveys of what our community members think about Cara Therapeutics and other stocks. Vote "Outperform" if you believe CARA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CARA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel